Compare · RMD vs SRTS
RMD vs SRTS
Side-by-side comparison of ResMed Inc. (RMD) and Sensus Healthcare Inc. (SRTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and SRTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 747.1x SRTS ($45.6M).
- RMD has hit the wire 9 times in the past 4 weeks while SRTS has been quiet.
- RMD has more recent analyst coverage (25 ratings vs 8 for SRTS).
- Company
- ResMed Inc.
- Sensus Healthcare Inc.
- Price
- -
- -
- Market cap
- $34.07B
- $45.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 8
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Sensus Healthcare Inc.
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target
Latest SRTS
- Director Sachetta Eric bought $225,616 worth of shares (64,841 units at $3.48), increasing direct ownership by 28% to 294,784 units (SEC Form 4)
- Director Sachetta Eric bought $66,682 worth of shares (20,633 units at $3.23), increasing direct ownership by 10% to 229,943 units (SEC Form 4)
- Director Sachetta Eric bought $112,904 worth of shares (34,697 units at $3.25), increasing direct ownership by 20% to 209,310 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Sardano Joseph C bought $60,486 worth of shares (20,000 units at $3.02), increasing direct ownership by 2% to 1,220,293 units (SEC Form 4)
- Director Sachetta Eric bought $97,850 worth of shares (31,000 units at $3.16), increasing direct ownership by 22% to 174,613 units (SEC Form 4)
- SEC Form 10-Q filed by Sensus Healthcare Inc.
- Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights
- Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026
- Sensus Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits